Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells. André T et al. Cancer Immunol Immunother. 2014 Oct 24. [Epub ahead of print]. Inhibition of Akt-signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. van der Waart AB et al. Blood. 2014 Oct 21. pii: blood-2014-05-578583. [Epub ahead of print]. Global…
DetailsPegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience. Cerchione C et al. Support Care Cancer. 2014 Oct 24. [Epub ahead of print]. Bisphosphonates do not delay engraftment after autologous SCT in patients with newly diagnosed myeloma. Oksman MJ et al. Bone Marrow Transplant. 2014 Oct…
DetailsHaematological cancer: Optimizing the treatment of multiple myeloma. Morgan GJ et al. Nat Rev Clin Oncol. 2014 Oct 28. doi: 10.1038/nrclinonc.2014.185. [Epub ahead of print]. The Role of Bendamustine in the Management of Plasma Cell Myeloma. Gertz MA. Leuk Lymphoma. 2014 Oct 27:1-5. [Epub ahead of print]. Non-hodgkin lymphoma risk and insecticide, fungicide and fumigant…
DetailsMultiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Blimark C et al. Haematologica. 2014 Oct 24. pii: haematol.2014.107714. [Epub ahead of print]. Drug-Induced Modulation of T Lymphocytes as a Potential Mechanism of Susceptibility to Infections in Patients with Multiple Myeloma During Bortezomib Therapy. Li J et al. Cell Biochem Biophys. 2014…
DetailsCyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. Tuchman SA et al. J Clin Apher. 2014 Oct 8. doi: 10.1002/jca.21360. [Epub ahead of print]. Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in chinese patients. Lin M et al. Adv Ther. 2014…
DetailsThis guideline outlines recommendations for the diagnosis and investigation of patients with suspected AL amyloidosis.
These guidelines outline recommendations for the management of patients with AL amyloidosis, including treatment, monitoring and how to measure response.
Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. Manasanch EE et al. Leuk Lymphoma. 2014 Sep 27:1-24. [Epub ahead of print]. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously…
DetailsFinger amyloidosis in a patient with myeloma. Tan J et al. Intern Med. 2014;53(18):2175-6. Epub 2014 Sep 15. Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist. Rosado FG et al. Mod Pathol. 2014 Sep 12. doi: 10.1038/modpathol.2014.117. [Epub ahead of print]. Systemic amyloidosis causing intestinal hemorrhage and…
DetailsPhase I Trial of Bortezomib and “Non-Hybrid “(Bolus) Infusion Schedule of Alvocidib (Flavopiridol) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms. Holkova B et al. Clin Cancer Res. 2014 Sep 23. pii: clincanres.0805.2014. [Epub ahead of print]. Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review. He X et al.…
Details